PILRA regulates microglial immunometabolism to reduce disease pathology as a candidate therapeutic target for Alzheimer’s disease

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

The Alzheimer’s disease (AD) genetic landscape identified microglia as a key disease-modifying cell type. A known AD protective variant in paired immunoglobulin-like type 2 receptor alpha (PILRA), shown to reduce risk in APOE4 carriers, is enriched in a cohort of healthy centenarians; however, mechanisms underlying protective effects in microglia are undefined. Here we identify biological functions of PILRA, an ITIM-domain containing receptor, in human iPSC-derived microglia (iMG) and chimeric AD mice. PILRA knockout (KO) in iMG rescued ApoE4-mediated immunometabolic deficits and prevented lipotoxicity via increased lipid storage, improved mitochondrial bioenergetics, and antioxidant activity. PILRA KO also enhanced microglial chemotaxis and attenuated inflammation. We show PPAR and STAT1/3 act as critical regulators of PILRA -dependent microglial functions. AD mice transplanted with human PILRA KO microglia exhibit reduced amyloid pathology and rescued synaptic markers. A high-affinity PILRA antibody phenocopies PILRA KO; therefore, PILRA is a pharmacologically tractable therapeutic target for AD.

Article activity feed